• Osiris Therapeutics Inc., of Columbia, Md., reported fourth-quarter revenues of $7.2 million, with most of that - $6 million - coming from sales of Osteocel. The company reported a net loss of $21.6 million for the quarter, and ended 2007 with $48.2 million in cash, including $30 million available under its credit line.

• Sepracor Inc., of Marlborough, Mass., posted Lunesta sales of $149.8 million for the fourth quarter and said full-year sales of the insomnia drug increased by 6.3 percent to $600.9 million. Overall revenues totaled $340 million for the three months ended Dec. 31, and Sepracor attributed a reduction from the previous year to the impact of the Centers for Medicare & Medicaid Services' 2007 decision to institute a new, bundled payment amount for Xopenex (levalbuterol HCl inhalation solution) and generic albuterol inhalation products. Net loss for the quarter was $5 million, or 5 cents per share. Those results include a $75 million up-front payment Sepracor made to Portuguese firm Bial SA to develop and commercialize Bial's epilepsy drug eslicarbazepine acetate in the U.S. and Canada. As of Dec. 31, Sepracor had about $1.1 billion in cash and investments.